Noble Corporation plc vs Smith & Nephew plc — how do they compare? Noble Corporation plc trades at $44.2 (market cap $7.10B), while Smith & Nephew plc trades at $29.95 (market cap $12.54B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Noble Corporation plc pays the higher dividend (4.5%). Which is the better fit depends on your goals.
| NE | SNN | |
|---|---|---|
Market Cap | $7.10B | $12.54B |
Sector | Technology | Health |
52-Week High | $54.37 | $38.70 |
52-Week Low | $26.61 | $28.73 |
Enterprise Value | $8.53B | $15.57B |
Dividend Yield | 4.5% | 2.65% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Smith & Nephew (SNN) trades at $30.08, down 0.1% with bearish technical signals. The company reported mixed Q2 2026 results with revenue growth below expectations, leading to a reduced full-year outlook. Fundamentals show strong profitability with 10.1% net margin and improving cash flow trends, though recent earnings misses have tempered sentiment.
Outlook remains cautious with analyst consensus at Hold (65% of coverage). Near-term risks include U.S. orthopedics weakness and competitive pressures, offset by robotics innovation and value-based care expansion. The stock offers stable fundamentals but faces execution challenges in key markets.
Trailing returns across standard periods
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →